ImmuPharma (AIM: IMM) has highlighted new academic research suggesting its lead drug candidate, P140, may have potential as a treatment for glioblastoma, one of the most aggressive and difficult-to-treat forms of brain cancer.
The AIM-listed biotechnology company pointed to a recently published study in the scientific journal Autophagy by researchers at the University of Murcia, which explores how the P140 peptide could be applied in glioblastoma treatment.
P140 is a synthetic peptide, a short chain of amino acids designed to target specific biological pathways, and remains ImmuPharma’s flagship development asset.
The company said it has been monitoring the Murcia research programme since 2024 and maintains regular contact with the research team. Management believes the findings support the broader scientific understanding of P140’s mechanism of action and align with existing research underpinning the programme.
Importantly, ImmuPharma stressed that its strategic focus remains firmly on developing P140 as a treatment for autoimmune diseases, where the asset is already being advanced through the clinical development pathway.
However, the latest research highlights the possibility of expanding P140’s therapeutic applications beyond autoimmune disorders. If future studies continue to demonstrate efficacy in oncology settings, glioblastoma could represent an additional long-term opportunity for the drug candidate.
While the work remains at an early research stage and is not yet part of ImmuPharma’s primary development strategy, the findings provide further evidence of the versatility of the P140 platform and the potential for broader commercial applications in the future.
For investors, the announcement adds another potential value driver to the company’s lead asset while leaving its core autoimmune disease development programme unchanged.
